Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octaplex vs Kcentra for VKA Reversal in Urgent Surgery
NCT02740335Phase 3Completed
- Sponsor
- Octapharma
- Start
- Jun 2017
- Primary completion
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
A Phase 3 trial of balfaxar in acquired coagulation factor deficiency, vitamin K antagonist-induced coagulopathy, sponsored by Octapharma. Started Jun 2017; status: completed.
02
Drugs
balfaxar
03
Conditions
acquired coagulation factor deficiencyvitamin K antagonist-induced coagulopathy
Beyond the preview
Go deeper on NCT02740335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02740335.